Americas · General news · Toronto Star

Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026

Published by Toronto Star · Canada 9 h ago

Detailed summary

Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to improving ...

Read the full article on Toronto Star Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.thestar.com)

Also worth reading

CBC News

Trump breaks silence on nationwide ground stop, demands more money for FAA infrastructure from Congress

Global News

Carney, Plamondon agree to Quebec summit and tackling homelessness

National Post

What Michael Chong wants you to understand about ‘big-borrowing, big-spending’ Mark Carney

CTV News

17-year-old brings AFC Toronto their first-ever NSL championship win

Le Devoir

«Confessions d’un enfant du siècle dernier» : mémoire et transmission

Mongabay Latam